|
HY-130571-100mg
|
MedChemexpress LLC
|
m-PEG9-Amine [CAS 211859-73-3]
|
|
Cancer-programmed cell death
|
|
|
HY-130571-250mg
|
MedChemexpress LLC
|
m-PEG9-Amine [CAS 211859-73-3]
|
|
Cancer-programmed cell death
|
|
|
HY-130571-50mg
|
MedChemexpress LLC
|
m-PEG9-Amine [CAS 211859-73-3]
|
|
Cancer-programmed cell death
|
|
|
HY-132161-1mg
|
MedChemexpress LLC
|
MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT [CAS 2378428-19-2]
|
|
Cancer-programmed cell death
|
|
|
HY-132161-5mg
|
MedChemexpress LLC
|
MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT [CAS 2378428-19-2]
|
|
Cancer-programmed cell death
|
|
|
HY-P80229-10uL
|
MedChemexpress LLC
|
Mre11 Antibody
|
|
|
|
|
HY-P80229-100uL
|
MedChemexpress LLC
|
Mre11 Antibody
|
|
|
|
|
HY-P80229-50uL
|
MedChemexpress LLC
|
Mre11 Antibody
|
|
|
|
|
HY-P80758-10uL
|
MedChemexpress LLC
|
MSR1 Antibody
|
|
|
|
|
HY-P80758-100uL
|
MedChemexpress LLC
|
MSR1 Antibody
|
|
|
|
|
HY-P80758-50uL
|
MedChemexpress LLC
|
MSR1 Antibody
|
|
|
|
|
HY-P80230-10uL
|
MedChemexpress LLC
|
Mst2 Antibody
|
|
|
|
|
HY-P80230-100uL
|
MedChemexpress LLC
|
Mst2 Antibody
|
|
|
|
|
HY-P80230-50uL
|
MedChemexpress LLC
|
Mst2 Antibody
|
|
|
|
|
HY-P80759-10uL
|
MedChemexpress LLC
|
mTOR Antibody
|
|
|
|
|
HY-P80759-100uL
|
MedChemexpress LLC
|
mTOR Antibody
|
|
|
|
|
HY-P80759-50uL
|
MedChemexpress LLC
|
mTOR Antibody
|
|
|
|
|
HY-P80231-10uL
|
MedChemexpress LLC
|
mTOR Antibody (YA281)
|
|
|
|
|
HY-P80231-100uL
|
MedChemexpress LLC
|
mTOR Antibody (YA281)
|
|
|
|
|
HY-P80231-50uL
|
MedChemexpress LLC
|
mTOR Antibody (YA281)
|
|
|
|
|
HY-P99181-1mg
|
MedChemexpress LLC
|
Mu padolimab [CAS 2451856-97-4]
|
|
COVID-19-anti-virus
|
|
|
HY-P99181-10mg
|
MedChemexpress LLC
|
Mu padolimab [CAS 2451856-97-4]
|
|
COVID-19-anti-virus
|
|
|
HY-P99181-5mg
|
MedChemexpress LLC
|
Mu padolimab [CAS 2451856-97-4]
|
|
COVID-19-anti-virus
|
|
|
HY-P99746-1mg
|
MedChemexpress LLC
|
Mu rlentamab [CAS 2058047-65-5]
|
|
|
|
|
HY-P99746-10mg
|
MedChemexpress LLC
|
Mu rlentamab [CAS 2058047-65-5]
|
|
|
|
